#datascience #dataanalysis #technology #clinicaltrials #opensource #rshiny #techtransformation

The opinions shared here do not represent the official position of Roche or Novartis.

We explore why clinical trials lag behind in innovation—even as the research side of drug development makes massive leaps. We’ll uncover why attracting top talent is critical to driving the industry forward, particularly in adopting open-source technologies. Dive into tools like R, test automation frameworks, and data abstractions, and learn how they’re reshaping tech transformation in clinical trials. Joining us are Novartis experts Orla Doyle and James Black to unpack the challenges and opportunities ahead.

• In this episode, you will learn:
• Why R and open-source tools are dethroning outdated proprietary systems
• How modern tools attract new talent and retain seasoned experts
• The persistent inefficiency puzzle in clinical data analysis
• Decentralized trials: balancing accessibility with data integrity
• Building regulatory trust in open-source and agile workflows
• AI’s future in trials, decentralized models, and global standards

Orla Doyle
► https://www.linkedin.com/in/orla-doyle-53a5019a/
James Black
► https://www.linkedin.com/in/epijim/
Nat Chrzanowska
https://www.linkedin.com/in/nat-chrzanowska/ 
__________________________________________
More about Appsilon:
► https://www.appsilon.com/
Appsilon empowers pharmaceutical and life sciences companies to leverage open-source technology for faster, data-driven decision-making in regulated environments. Schedule a free consultation with our expert
► https://www.appsilon.com/contact-us 
__________________________________________
For more insights about how technology helps scientists push the boundaries of data analysis and reporting check out our blog:
► http://appsilon.com/blog 
LinkedIn: https://www.linkedin.com/company/appsilon/